Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03204812 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Castration-Resistant Prostate Carcinoma
Metastatic Malignant Neoplasm in the Bone
Prostate Adenocarcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8

Interventions

BIOLOGICAL: Durvalumab
BIOLOGICAL: Tremelimumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]